Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Front Biosci 1998 Nov 01;3:E193-203
Date
10/30/1998Pubmed ID
9792895DOI
10.2741/a377Scopus ID
2-s2.0-0032209325 (requires institutional sign-in at Scopus site) 21 CitationsAbstract
Adjuvant 5-fluorouracil and concurrent radiation may improve survival following complete surgical resection in patients with pancreatic adenocarcinoma. However, the morbidity and prolonged recovery associated with pancreaticoduodenectomy frequently prevents the timely delivery of postoperative chemoradiation. Therefore, the University of Texas M.D. Anderson Cancer Center (MDACC) has investigated the use of neoadjuvant chemoradiation in potentially resectable pancreatic cancer. We have incorporated a standardized approach to pretreatment staging, operative technique and pathologic evaluation. Our initial experience suggests that preoperative chemoradiation is well tolerated and may reduce loco-regional recurrence. Patients treated with rapid-fractionation preoperative chemoradiation had a significantly shorter duration of treatment compared with patients who received postoperative chemoradiation or standard-fractionation preoperative chemoradiation. New and more potent radiation-sensitizing agents such as gemcitabine may further enhance local control. Novel therapies directed at specific molecular events involved in pancreatic tumorigenesis may be incorporated into preoperative and postoperative regimens to attempt to reduce systemic relapse.
Author List
Breslin TM, Janjan NA, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Evans DBAuthor
Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenocarcinomaChemotherapy, Adjuvant
Combined Modality Therapy
Humans
Neoadjuvant Therapy
Neoplasm Staging
Pancreatic Neoplasms
Pancreaticoduodenectomy
Radiation-Sensitizing Agents
Radiotherapy, Adjuvant
Survival Rate
Tomography, X-Ray Computed
